Hey Arsen, Sensesonics is a hardware company and not a competitor for ALRT which is a data management company. Senseonics recently just relaunched their implantable CGM called Eversense XL in Europe through a exclusivity partnership with Ascensia on distribution. The implantable had previously only been approved for 3 months use and is now approved for 6 months in Europe and they are applying for FDA clearance on 365 day use.
Implantable CGM's are in theory a great idea compared to wearables like the libre or G6, but they require minor surgery so even at 6 months I would not think this will catch on, but they may see some success if they get approval for a year. Wearing a receiver is still required over where they place the implantable but it can be taken on and off with daily sticky pads compared to a regular CGM that must stay on for the whole 2 weeks.
If anything, Sensesonics is just another example of why ALRT is needed in the diabetes market. All that data from an implantable or a wearable CGM has to be converted into useful information. A doctor is not going to comb over weeks or months of data trying to figure out insulin dosing or therapy advancements. ALRT does that automatically and alerts the doctor of need for change transforming diabetes from self-care to monitored proactive care.
Hope that helps, let me know if you have any other questions
News 
Market Data 
Discover 
